Global Cancer Diagnostics Market - Forecasts From 2018 to 2023

November 2018 | 110 pages | ID: GF8D6136C23EN
Knowledge Sourcing Intelligence LLP

Abstracts

The global cancer diagnostics market is projected to grow at a CAGR of 14.22%, increasing from US$9.050 billion in 2017 to US$20.099 billion in 2023. As per data by WHO, cancer is the second leading cause of death globally with an estimated 9.6 million deaths in 2018, with the lung, colorectal, stomach, lever and breast cancer being the most common causes of cancer death. Cancer diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumour type, location, extent and stage. Correct diagnosis of the disease is important to develop an individualized cancer treatment plan. Cancer diagnostics market is expected to show a significant growth during the given forecast period. The rise in the market may be attributed to the rising prevalence of the disease coupled with the rising awareness among the people regarding the disease. Initiatives undertaken by governments and global health organizations to spread awareness about cancer will also boost the market during the given forecast period. However, high cost of diagnostic imaging systems along with the high capital investments might restrain the market for cancer diagnostics during the given forecast period.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global cancer diagnostics market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global cancer diagnostics market.

Major industry players profiled as part of the report are bioMérieux, Inc, Arquer Diagnostics Ltd and Castle Biosciences, Inc. among others.

Segmentation

By Diagnostic Procedures
Laboratory Tests
Imaging Procedures
Biopsy
By Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Stomach Cancer
Other Cancers
By End Users
Hospitals and Clinics
Diagnostic Centres
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. KEY FINDINGS OF THE STUDY

4. MARKET DYNAMICS

4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis

5. GLOBAL CANCER DIAGNOSTICS MARKET FORECAST BY DIAGNOSTIC PROCEDURES

5.1. Laboratory Tests
5.2. Imaging Procedures
5.3. Biopsy

6. GLOBAL CANCER DIAGNOSTICS MARKET FORECAST BY APPLICATION

6.1. Lung Cancer
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Skin Cancer
6.5. Stomach Cancer
6.6. Other Cancers

7. GLOBAL CANCER DIAGNOSTICS MARKET FORECAST BY END USERS

7.1. Hospitals and Clinics
7.2. Diagnostic Centres

8. GLOBAL CANCER DIAGNOSTICS MARKET FORECAST BY GEOGRAPHY (US$ BILLION)

8.1. North America
  8.1.1. The U.S
  8.1.2. Canada
  8.1.3. Mexico
  8.1.4. Others
8.2. South America
  8.2.1. Brazil
  8.2.2. Argentina
  8.2.3. Others
8.3. Europe
  8.3.1. U.K.
  8.3.2. France
  8.3.3. Germany
  8.3.4. Italy
  8.3.5. Others
8.4. Middle East and Africa
  8.4.1. Saudi Arabia
  8.4.2. UAE
  8.4.3. Israel
  8.4.4. Others
8.5. Asia Pacific
  8.5.1. China
  8.5.2. India
  8.5.3. Australia
  8.5.4. South Korea
  8.5.5. Others

9. COMPETITIVE INTELLIGENCE

9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals

10. COMPANY PROFILES

10.1. bioMérieux, Inc
  10.1.1. Overview
  10.1.2. Financials
  10.1.3. Product and Services
  10.1.4. Recent Developments
10.2. F. Hoffmann-La Roche Ltd
  10.2.1. Overview
  10.2.2. Financials
  10.2.3. Product and Services
  10.2.4. Recent Developments
10.3. Sienna Cancer Diagnostics
  10.3.1. Overview
  10.3.2. Financials
  10.3.3. Product and Services
  10.3.4. Recent Developments
10.4. Insight Genetics
  10.4.1. Overview
  10.4.2. Financials
  10.4.3. Product and Services
  10.4.4. Recent Developments
10.5. MetaCell
  10.5.1. Overview
  10.5.2. Financials
  10.5.3. Product and Services
  10.5.4. Recent Developments
10.6. Cancer Genetics Inc.
  10.6.1. Overview
  10.6.2. Financials
  10.6.3. Product and Services
  10.6.4. Recent Developments
10.7. Breath Diagnostics, Inc.
  10.7.1. Overview
  10.7.2. Financials
  10.7.3. Product and Services
  10.7.4. Recent Developments
10.8. Arquer Diagnostics Ltd
  10.8.1. Overview
  10.8.2. Financials
  10.8.3. Product and Services
  10.8.4. Recent Developments
10.9. Metabiomics
  10.9.1. Overview
  10.9.2. Financials
  10.9.3. Product and Services
  10.9.4. Recent Developments
10.10. Castle Biosciences, Inc.
  10.10.1. Overview
  10.10.2. Financials
  10.10.3. Product and Services
  10.10.4. Recent Developments